RxDoctor Payments Data

Jennifer Rupp, MD

Infectious Disease · Durango, CONPI 1467675827

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 45 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Viiv Healthcare Company at 43.1% of the total. Reporting peaked in 2019 at $228 and has fallen 51.0% since, to $112 in 2024.

$826in general payments, 2019–2025

Across 45 payments — averaging $18.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$356
  • Gilead$264
  • Merck$109
  • Organogenesis Inc.$47
  • Sanofi Pasteur Inc.$19
  • AbbVie$16
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$826100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$826 in reported general payments places this provider in the 70th percentile of 146 infectious disease providers in Colorado.

See all infectious disease providers in Colorado

Medicare billing

Part B allowed, 2024
$58,833
Medicare patients
211
Services billed
551

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala154$607,158
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf45$212,312
TivicayDolutegravir Sodium49$149,087
OdefseyEmtricitab/Rilpiviri/Tenof Ala27$119,643
GenvoyaElviteg/Cob/Emtri/Tenof Alafen21$88,798
JulucaDolutegravir/Rilpivirine16$76,251
DescovyEmtricitabine/Tenofov Alafenam17$55,273
DovatoDolutegravir Sodium/Lamivudine13$36,374
TrulicityDulaglutide26$22,061
OzempicSemaglutide18$16,523
RexultiBrexpiprazole11$16,514
JardianceEmpagliflozin11$10,008
VascepaIcosapent Ethyl17$7,500
Daptomycin11$4,514
Cefadroxil91$4,312

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$264$751,229192 claims
Viiv Healthcare CompanyTivicay, Juluca, Dovato$356$261,71278 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 146 infectious disease providers in Colorado.

Other infectious disease in Durango

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →